Abstract
The value of misonidazole in advanced head and neck cancer was examined in 3 ways and the preliminary results are reported in a randomized study with large fractions of irradiation, when misonidazole appeared to confer no advantage; whereas in previously (partially) treated patients misonidazole was possibly useful. The combination of hyperbaric oxygen and misonidazole did not appear to be toxic.
Full text
PDF![314](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa16/2149372/0303e3ad4815/brjcancersuppl00061-0328.png)
![315](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa16/2149372/af3eb7df1984/brjcancersuppl00061-0329.png)
![316](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa16/2149372/c0bec9741eaa/brjcancersuppl00061-0330.png)
![317](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa16/2149372/45f4ee02a0f8/brjcancersuppl00061-0331.png)